Key Highlights

  • Verici Dx Plc (LSE:VRCI) gained 7.14% on 7 October 2026.
  • Tutivia testing volumes rose 32% quarter-on-quarter to 392 tests in Q1 2026.
  • Ordering centres now represent about 20% of annual US kidney transplants, supported by Medicare and expanding payer coverage.
  • New agreements in 2026 include a Blue Cross Blue Shield of Illinois deal and an Olink certified service provider agreement.

Verici Dx Shares Climb on 7 October 2026

Verici Dx Plc (LSE:VRCI), the developer of advanced clinical diagnostics for organ transplantation, rose 7.14% on 7 October 2026. The AIM-quoted company, part of the FTSE AIM All-Share Index, has seen renewed interest as its flagship Tutivia blood test gains traction in US kidney transplant centres.

Verici Dx has had a difficult few years on the stock market, but 2026 has brought a series of commercial milestones that suggest its products are moving from early launch into broader clinical use.

Why Verici Dx Shares Rose 7.14%

No specific new announcement had been confirmed as the trigger for the move at the time of writing. However, the timing is notable. In 2025, Verici Dx published its third-quarter update on Tutivia adoption in early October, so investors may be positioning for a similar update on testing volumes and centre onboarding for the third quarter of 2026.

The broader driver is commercial momentum. In the first quarter of 2026, Tutivia testing volumes rose 32% quarter-on-quarter to 392, up from 296 in the fourth quarter of 2025, which was significantly ahead of management expectations. Each new quarter of growth strengthens the case that the test is becoming part of routine post-transplant monitoring.

Payer coverage is also expanding. Tutivia already has Medicare coverage with pricing of $2,650 per test, it has been approved by additional state Medicaid programmes, and in June 2026 the company announced an agreement with Blue Cross Blue Shield of Illinois.

Understanding Tutivia and the Verici Dx Portfolio

Tutivia is a post-transplant blood test that helps detect a patient's risk of acute kidney rejection, including borderline, T cell-mediated and antibody-mediated rejection. It aims to give clinicians earlier and more precise information than traditional measures.

Verici Dx also has Clarava, a pre-transplant risk assessment test licensed to Thermo Fisher Scientific, which brings milestone and Royalty potential, and Protega, a test aimed at long-term fibrosis monitoring. The company is developing a urine-based proteomics programme and clinical trial support services.

Recent Corporate Milestones

In June 2026, Verici Dx raised about £2.5 million through a placing, alongside a retail offer of up to £200,000, to fund commercial growth. The same month, it received New York State clinical laboratory certification, opening access to an important US market. In August 2026, it signed a certified service provider agreement with Olink, extending its capabilities in proteomics services.

For 2025, Revenue was about $3.7 million, including roughly $2.9 million from Tutivia and $0.8 million from Thermo Fisher milestone payments. The adjusted EBITDA loss was $6.2 million.

Why Investors Are Watching LSE:VRCI

Verici Dx is in focus because it is approaching the point where test volumes and reimbursement could drive meaningful recurring revenue. The US kidney transplant testing market is estimated at about $900 million, with a significant portion considered unaddressed.

Investors are watching third-quarter testing volumes, the number of ordering centres, additional private payer agreements, cash runway and any further milestones from the Thermo Fisher partnership.

Risks to Consider

Verici Dx remains loss-making and reliant on external funding, so further Equity raises could dilute shareholders. Adoption of new diagnostics can be slower than expected, and reimbursement decisions from insurers can be unpredictable. Competition in transplant diagnostics is significant. The company previously cut revenue expectations for its services business, which hit the share price in 2025. As a small AIM stock, the shares can be highly volatile.

Outlook

The 7.14% gain on 7 October 2026 reflects growing confidence that Tutivia is gaining clinical acceptance in the United States. With rising test volumes, Medicare and expanding private coverage, and new laboratory credentials, LSE:VRCI has several building blocks in place. The next update on testing volumes will be central to whether the shares can maintain this positive momentum.